Therapeutic potential of stem cells in type 1 diabetes: challenges for their implementation in Argentina

Daniela Villada Escobar; Karina Bustamante Galarza

doi:10.59471/ijhsc202557

Authors

Daniela Villada Escobar Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Buenos Aires, Argentina Author
Karina Bustamante Galarza Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Buenos Aires, Argentina Author

DOI:

https://doi.org/10.59471/ijhsc202557

Keywords:

type 1 diabetes, stem cells, immunomodulation, regulation, Argentina

Abstract

Type I diabetes mellitus was described as an autoimmune disease that caused the destruction of pancreatic beta cells. The use of umbilical cord stem cells, especially mesenchymal stem cells, was investigated for their ability to regenerate beta cells and modulate the immune system. In 2024, the case of a patient who produced insulin following a transplant of induced pluripotent stem cells was reported, although the treatment was still in the experimental phase. In Argentina, current legislation guaranteed medical coverage for traditional medicines, but did not contemplate advanced therapies such as the use of stem cells. The country adopted a cautious stance regarding their regulation, and key challenges were identified such as the need for clinical trials, adequate regulation, equity in access and public education to advance towards a safe and effective application of these therapies.

References

Argentina.gob.ar. Diabetes Mellitus [Internet]. 2017 ago 9 [citado 2025 abr 4]. Disponible en: https://www.argentina.gob.ar/salud/glosario/diabetes

Armson BA, Allan DS, Casper RF. Umbilical cord blood: counselling, collection, and banking. J Obstet Gynaecol Can. 2015 Sep;37(9):832-44. doi:10.1016/S1701-2163(15)30157-2

Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2004;22(4):625-34. doi:10.1634/stemcells.22-4-625

Eaves CJ. Hematopoietic stem cells: concepts, definitions, and the new reality. Blood. 2015 Apr 23;125(17):2605-13. doi:10.1182/blood-2014-12-570200

El-Hazmi MA, Warsy AS. Prevalence of overweight and obesity in diabetic and non-diabetic Saudis. East Mediterr Health J. 2000;6(2-3):276-82.

Ishii T, Eto K. Fetal stem cell transplantation: past, present, and future. World J Stem Cells. 2014 Sep 26;6(4):404-20. doi:10.4252/wjsc.v6.i4.404

Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, et al. Isolation and characterization of Human Umbilical Cord Mesenchymal Stem Cells with Hematopoiesis-Supportive Function and Other Potentials». Haematologica 91, n.o 8 (agosto de 2006): 1017-26.

Nicolau F, Quetglas M, Ramis JM, Monjo M, Arbós A, Gayà A, Calvo J, Muncunill J. Obtención de células madre mesenquimales a partir de cordones umbilicales procedentes de un programa altruista de donación de sangre de cordón. Inmunología (1987). 2013;:3-11.

Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330-7. doi:10.1634/stemcells.2004-0013.